Silver Creek Pharmaceuticals, Inc.
1 more in force is now held by another company
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
0
Ending by 2030
May 2031
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Dec 13, 2026The maintenance fee for Bi-Specific Fusion Proteins (US 11,673,970) comes due Dec 13, 2026. Unpaid by Jun 14, 2027, it lapses early.
- 1 fee due May 14, 2027The maintenance fee for Bi-Specific Fusion Proteins (US 11,814,443) comes due May 14, 2027. Unpaid by Nov 15, 2027, it lapses early.
- 2 fees due Jul 19 to 23, 2027 · next Jul 19
- 1 fee due Oct 28, 2027The maintenance fee for Method of Protecting Tissue from Damage by Administering a Bi-Specific Therapeutic Protein Comprising Insulin-Like Growth Factor 1 (IGF-1) and Annexin A5 (US 10,633,425) comes due Oct 28, 2027. Unpaid by Apr 28, 2028, it lapses early.
Recent changes
- 1 of the patents on this record was granted since Aug 23, 2026
- Aug 25 US 12,715,937 Bi-Specific Fusion Proteins
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 9,238,080 | Bi-specific fusion proteins In force · Medium confidence | In force | Medium confidence | |
| US 9,718,892 | A method of treating myocardial infarction by administering a bi-specific fusion protein In force · High confidence | In force | High confidence | |
| US 9,982,060 | Bi-Specific Fusion Proteins In force · High confidence | In force | High confidence | |
| US 10,858,450 | Bi-Specific Fusion Proteins In force · High confidence | In force | High confidence | |
| US 10,988,547 | Bi-Specific Fusion Proteins In force · High confidence | In force | High confidence | |
| US 11,814,443 | Bi-Specific Fusion Proteins In force · High confidence | In force | High confidence | |
| US 12,715,937 | Bi-Specific Fusion Proteins In force · Medium confidence | In force | Medium confidence | |
| US 12,698,347 | Bi-Specific Fusion Proteins In force · Medium confidence | In force | Medium confidence | |
| US 11,673,970 | Bi-Specific Fusion Proteins In force · High confidence | In force | High confidence | |
| US 8,691,771 | Bi-Specific Fusion Proteins for Tissue Repair In force · Medium confidence | In force | Medium confidence |
Also on record, not counted in the 15: 1 patent in force now held by others. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
4 pending · 1 no status recorded